Explore the Agenda
8:00 am Morning Refreshments
8:50 am Chair’s Opening Remarks
Extending the Therapeutic Horizon to Treat Neurological Disorders, Addiction & Women’s Health to Understand the Emerging Opportunities of GLP-1s
9:00 am Translating GLP-1 Agonism to Uncover Novel Mechanisms for Neuroprotection in Alzheimer’s and Parkinson’s Disease
- Investigating how GLP-1-based therapies influence the brain beyond feeding behavior regulation – and their relevance for neurodegenerative disease
- Reconsidering the role of glial cells in mediating therapeutic effects of GLP-1R agonism
- Tracing conserved brain responses to GLP-1 modulation across systems
9:30 am Session Reserved for Perspectum
10:00 am Unlocking the Potential of GLP-1s to Treat Addiction & Substance Use Disorders to Reduce Cravings & Impulsivity to Provide a Novel Treatment Option
- Modulating brain reward circuits to reduce cravings and impulsivity, offering a novel, non-addictive therapeutic option for substance use disorders
- Expanding the therapeutic scope of GLP-1s to offer a new treatment for addiction to help address a major public health crisis with a new mechanism
- Integrating GLP-1 therapy with behavioural interventions to enhance treatment efficacy, leading to better patient outcomes and a higher rate of long-term recovery
10:30 am Morning Break & Networking
11:00 am Optimizing GLP-1s for Women’s Health Conditions, Including PCOS to Address Hormonal Imbalances & Improve Metabolic Function Leading to Better Clinical Outcomes
- Addressing hormonal imbalances through targeted GLP-1 receptor agonism to regulate menstrual cycles and improve fertility in patients with polycystic ovary syndrome (PCOS)
- Improving insulin sensitivity in women with PCOS to enhance metabolic function, reducing the long-term risk of developing type 2 diabetes and cardiovascular disease
- Providing a holistic treatment option for women’s health to manage complex comorbidities in one therapy and improves overall well-being and quality of life
11:30 am Session Reserved for Antaros Medical
12:00 pm Fire-Side Discussion: Repurposing GLP-1s to Treat Alzheimer’s & Parkinson’s to Improve Cognitive Function & Reduce Neuroinflammation to Create a New Therapeutic Avenue
- Diversifying treatment opportunities by investigating GLP-1s for new indications like neurological disorders and addiction to unlock their full therapeutic potential and expand their use beyond cardiometabolic health
- Providing new hope for patients by researching next-generation applications to create therapeutic options for conditions with limited treatments
- Expanding the clinical horizon with a wider range of applications for GLP-1s to establish these therapies as a foundational class of drugs for modern medicine
12:30 pm Lunch
Redefining the Patient Journey by Improving Side Effects & Routes of Administration to Enhance Patient Comfort & Provide a Better Quality of Life Long-Term
1:30 pm Maximizing Efficacy, Minimizing Risk by Leveraging Peripheral CB1 Antagonism in Combination with GLP-1 Agonists to Advance the Obesity Treatment Paradigm
- Demonstrating the potential of combination therapy utilizing a peripherally acting CB1 antagonist (namacimab) with semaglutide, as evidenced by recent data showing enhanced weight loss and strong efficacy results
- Mitigating CNS-mediated side effects by focusing on peripheral CB1 receptors in adipose and muscle tissue, establishing a path for long-term patient comfort and adherence that is critical to redefining the patient journey
- Defining the strategy for next-generation metabolic therapeutics that layer novel mechanisms onto incretin backbones to provide superior clinical outcomes and establish a more robust, long-term safety profile
2:00 pm Redefining the Patient Experience with a First-in-Class Oral, Gut- Restricted Agonist to Improve Tolerability
- Utilizing an oral, non-systemic bitter taste receptor (TAS2R) agonist to bypass the need for injections and transform the route of administration for metabolic therapeutics
- Stimulating the body’s own endogenous secretion of multiple gut hormones locally in the GI tract to achieve a more physiological response with superior gastrointestinal tolerability
- Enhancing long-term patient adherence and quality of life by providing a simple, pill based therapeutic option that avoids injection-site reactions and systemic side effects
2:30 pm Managing Gastrointestinal Side Effects of GLP-1 Therapies Through Targeted Receptor Agonism to Improve Patient Tolerability & Increase Treatment Adherence
- Minimizing common GI side effects, such as nausea and vomiting, through targeted receptor agonism to improve patient tolerability and increase long-term treatment adherence
- Designing therapies to selectively activate GLP-1 receptors in specific tissues to reduce systemic GI effects and provide patients with a better quality of life while on treatment
- Improving patient comfort with fewer gastrointestinal symptoms to ensure greater medication persistence, leading to better and more sustained clinical outcomes
3:00 pm Afternoon Break & Networking
3:30 pm Redefining the Patient Journey by Leveraging Oral MPC Modulation to Enhance GLP-1 Tolerability and Preserve Lean Mass
- Utilizing a novel oral Mitochondrial Pyruvate Carrier (MPC) modulator (azemiglitazone) with GLP-1 Receptor Agonists, as evidenced by preclinical and early clinical data showing enhanced metabolic control (improved insulin sensitivity, reduced liver fat) and synergistic efficacy in reducing underlying metabolic dysfunction in Type 2 Diabetes and MASH
- Focusing on the MPC modulator’s potential to preserve or increase lean mass while optimizing fat loss, establishing a path for long-term patient health and adherence that is critical to redefining the patient journey beyond mere weight reduction
- Defining the strategy for next-generation metabolic therapeutics that layer novel oral, non-incretin mechanisms onto incretin backbones to significantly enhance patient comfort and compliance by allowing for lower, better-tolerated doses of the GLP-1 component and establishing a more robust, long-term safety profile
4:00 pm Panel Discussion: Collating the Lessons Learned from FDA Approved Drugs to Inform the Future of GLP-1 Based Therapies & Ensure a Next- Generation of More Patient Centered Approaches
- Broadening the therapeutic scope of GLP-1s as the new frontier for a wide range of new applications, such as cardiovascular disease, neurodegenerative disorders and ageing, offering patients a more comprehensive approach to health beyond just weight loss
- Enhancing drug delivery for patient success to improve patient adherence through less frequent administration, including once-a-month injections and oral medications, providing a convenient and less intrusive treatment experience that supports longterm adherence
- Integrating a complementary ecosystem of care for collaborative approach of chronic drugs, advanced combinations, and procedural solutions that work together to create a personalized treatment plan for each patient, maximizing chances of achieving sustainable metabolic health